PAOG To Extend CBD Nutraceuticals Reach Into $3.8 Billion Market
February 04 2021 - 9:51AM
InvestorsHub NewsWire
Sandusky, OH --
February 4, 2021 -- InvestorsHub NewsWire -- PAO Group, Inc.
(USOTC:
PAOG) today revealed plans to expand its nutraceutical product
reach. The company plans to produce nutraceuticals for
additional applications beyond the current focus on care
for those
experiencing issues associated with Chronic Obstructive Pulmonary
Disorder (COPD).
Last year,
PAOG acquired
RespRx from Kali-Extracts, Inc. (OTC
Pink: KALY). RespRx is a cannabis treatment under development
for Chronic Obstructive Pulmonary Disorder (COPD) derived from a
patented cannabis extraction method - U.S. Patent No. 9,199,960
entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT
MATERIALS INCLUDING THE CANNABIS
PLANT."
In addition to
PAOG’s ongoing efforts to develop a pharmaceutical treatment for
COPD, the company has announced engaging with
the Puerto Rico Consortium for Clinical Investigation (PRCCI) to
assist PAOG with developing its proprietary Cannabidiol (CBD)
extract into a nutraceutical product to provide care for those
experiencing issues associated with Chronic Obstructive Pulmonary
Disorder (COPD).
Today, PAOG is revealing for the first
time a broader nutraceutical development initiative with plans to
produce nutraceuticals for additional applications. The CBD
nutraceutical market was valued at $3.8
billion in 2018 forecasted to grow at CAGR of over
18%.
PAOG plans to establish a revenue stream
this year from its nutraceuticals’ initiative adding to its
recently confirmed a $300,000 sales agreement executed by the
company’s cannabis cultivation subsidiary. PAOG anticipates
approximately $50,000 in revenue per quarter for six quarters
starting with an estimated $50,000 in revenue expected to be
reported for Q4 2020.
Last summer, PAOG acquired a cannabis
cultivation business from Puration, Inc. (USOTC:
PURA). The acquisition was made in conjunction with
PAOG’s overall strategy to refresh and renew its overall cannabis
healthcare industry strategy.
PAOG plans to
develop and distribute its CBD nutraceuticals with Alkame Holdings,
Inc. (OTC
Pink: ALKM) as a copacker and North American Cannabis Holdings,
Inc. (OTC
Pink: USMJ) as a
distributor.
Learn more about
PAOG at www.paogroupinc.com.
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT
INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
North American Cannabis (CE) (USOTC:USMJ)
Historical Stock Chart
From Apr 2024 to May 2024
North American Cannabis (CE) (USOTC:USMJ)
Historical Stock Chart
From May 2023 to May 2024